Cancer Immunology Reserch

Cancer Immunol Res. 2025 Apr 22. doi: 10.1158/2326-6066.CIR-24-0306. Online ahead of print. ABSTRACT Spontaneous remission in patients with various cancers has been reported. Some patients with adult T-cell leukemia-lymphoma (ATL), have experienced spontaneous remission, although mechanisms for this remain unknown. In this study, we analyzed ATL cells and human T-cell leukemia virus type 1 (HTLV-1) … Read more

Cancer Immunol Res. 2025 Apr 22. doi: 10.1158/2326-6066.CIR-24-0127. Online ahead of print. ABSTRACT NEDDylation is a post-translational modification whereby the ubiquitin-like molecule NEDD8 is attached to protein substrates in a process dependent on NEDD8 activating enzyme regulatory subunit (NAE1). NEDDylation is emerging as a regulator of cancer biology, but its precise role in antitumor immunity … Read more

Cancer Immunol Res. 2025 Apr 18. doi: 10.1158/2326-6066.CIR-24-0387. Online ahead of print. ABSTRACT Although initially assumed to be similar, immune checkpoint inhibitor (ICI)-induced autoimmunity can differ from spontaneous autoimmune disease regarding clinical presentation, pathogenesis and therapy. Despite limited pathogenetic understanding, ICI-induced colitis (irColitis), a common adverse event during ICI therapy, is treated analogously to its … Read more

Cancer Immunol Res. 2025 Apr 18:OF1-OF20. doi: 10.1158/2326-6066.CIR-24-0630. Online ahead of print. ABSTRACT Detection of disseminated cancer cells (DCC) in the bone marrow (BM) of patients with breast cancer is a critical predictor of late recurrence and distant metastasis. Conventional therapies often fail to completely eradicate DCCs in patients. In this study, we demonstrate that … Read more

Cancer Immunol Res. 2025 Apr 16. doi: 10.1158/2326-6066.CIR-24-1050. Online ahead of print. ABSTRACT CAR T-cell therapy has improved outcomes for patients with chemotherapy-resistant B-cell malignancies. However, CAR T-cell treatment of patients with solid cancers has been more difficult, in part because of the heterogeneous expression of tumor-specific cell surface antigens. Here, we describe the generation … Read more

Cancer Immunol Res. 2025 Apr 15:OF1-OF15. doi: 10.1158/2326-6066.CIR-24-0894. Online ahead of print. ABSTRACT T-cell senescence occurs in the tumor microenvironment (TME) and influences cancer outcomes, as well as the effectiveness of immunotherapies. The TME triggers this T-cell senescence via multiple pathways, including persistent stimulation with tumor-associated antigens, altered metabolic pathways, and activation of chronic inflammatory … Read more

Cancer Immunol Res. 2025 Apr 11. doi: 10.1158/2326-6066.CIR-24-0333. Online ahead of print. ABSTRACT The optimal means to prime for effective anti-tumor immunity in a cancer patient remains elusive in the current era of checkpoint blockade. Crafting a strategy to amplify CD8+ T cells while blocking regulatory cells should increase immunotherapy efficacy. Biomaterial carriers have been … Read more

Cancer Immunol Res. 2025 Apr 10. doi: 10.1158/2326-6066.CIR-24-0807. Online ahead of print. ABSTRACT The lack of response of glioblastoma (GBM) to immunotherapy is closely related to the limited number of T cells in the tumor microenvironment (TME). However, it is still not known why GBM is characterized by an immune-cold TME with reduced CD8+ T-cell … Read more

Cancer Immunol Res. 2025 Apr 2;13(4):453. doi: 10.1158/2326-6066.CIR-13-4-WWR. NO ABSTRACT PMID:40170562 | DOI:10.1158/2326-6066.CIR-13-4-WWR

Cancer Immunol Res. 2025 Apr 1. doi: 10.1158/2326-6066.CIR-24-0746. Online ahead of print. ABSTRACT Philadelphia-like acute lymphoblastic leukemia (Ph-like ALL) is a molecularly distinct tyrosine kinase-driven cancer that has a high relapse rate and poor response toward combinatorial chemotherapy. Tyrosine kinase inhibitors (TKI) in the clinic improve the survival of patients with Ph-like ALL. Engineered antibody … Read more